by Neil Turner, Editor, Far East Focus, published by Nicholas Hall & Company
A recent Ernst & Young survey of 230 multinationals revealed that for them the newly industrializing nations of Asia ranked as the most important emerging markets in the world. This was particularly the case for US-based companies, which have trailed their European and Japanese rivals in the rush to cultivate new alternatives to the mature markets of the West.
Given the hoopla surrounding its open- door economic policy, it comes as no great surprise to find that China was voted overwhelmingly the most attractive of all the world's emerging markets. No surprise either that India - apparently set to follow a similar path to China - was voted third most attractive emerging market in the world. Separating China and India was Indonesia, itself no lightweight with the fifth largest population in the world (estimated at 187 million), but certainly no match for the billion-plus consumer markets of China and India.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze